U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06874140) titled 'Proteomic Study of Chuanhong Zhongfeng Capsule in the Treatment of ACI' on Feb. 26.
Brief Summary: Acute cerebral infarction is characterized by high disability rate and high recurrence rate, which poses a great threat to the life and health of the nation. Proteomics technology is a holistic and comprehensive understanding of disease mechanism, cell metabolism and other processes at the protein level. The correlation between acute cerebral infarction and proteomics has become a hot spot of clinical and basic research in recent years. Chuanhong Zhongfeng capsule was developed by Ren Jixue, a master of national medicine, and clinical...